1. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
   Xin Su et al, 2024, Journal of Translational Medicine CrossRef
2. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
   Antero Salminen, 2024, Journal of Molecular Medicine CrossRef
3. A new strategy for immunotherapy of microsatellite‐stable (MSS)‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD‐1/PD‐L1 inhibitors
   Lingli Cai et al, 2024, Immunology CrossRef
4. Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142–5p/PD-L1 axis
   Junjun Ling et al, 2022, Archives of Biochemistry and Biophysics CrossRef
5. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer
   Giedrė Gurevičienė et al, 2024, Medicina CrossRef
6. Epigenome-Driven Strategies for Personalized Cancer Immunotherapy
   Gabriel Rocha et al, 2023, Cancer Management and Research CrossRef
7. Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma
   Jianpeng Wang et al, 2024, Clinics and Research in Hepatology and Gastroenterology CrossRef